<DOC>
	<DOCNO>NCT02519036</DOCNO>
	<brief_summary>This study test safety , tolerability , pharmacokinetics pharmacodynamics multiple ascend dos IONIS-HTTRx administer intrathecally adult patient early manifest Huntington 's Disease .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics IONIS-HTTRx Patients With Early Manifest Huntington 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Key Diagnosed early manifest Huntington 's disease Male female , age 25 65 year , inclusive , time informed consent Able willing meet study requirement , include travel Study Center participation procedure measurement study visit Have trial partner reliable , competent least 18 year age , willing accompany patient select trial visit available Study Center phone need Able tolerate MRI scan , blood draw lumbar puncture Reside within 4 hour travel Study Center Key Clinically significant medical condition , severe chorea , active suicidal ideation condition would make patient unsuitable inclusion could interfere patient participate completing study Recent treatment another investigational drug , biological agent , device Prior treatment antisense oligonucleotide ( include siRNA ) Any history gene therapy cell transplantation experimental brain surgery Presence implant shunt drainage CSF implant CNS catheter History postlumbarpuncture headache moderate severe intensity and/or blood patch Malignancy within 5 year Screening , except basal squamous cell carcinoma skin carcinoma situ cervix successfully treat Hospitalization major medical surgical procedure involve general anesthesia within 12 week Screening plan study</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Huntington 's Disease</keyword>
	<keyword>HTTRx</keyword>
	<keyword>Early Manifest Huntington 's Disease</keyword>
</DOC>